Answers are grounded in this paper and cite their sources.
Prolonged survival, including cure in some patients, may be achieved in adult patients receiving intensive chemotherapy (ICT) for acute myeloid leukaemia (AML).1 2 Although not all patients are fit to receive ICT, disparities exist.3 Especially, large epidemiological studies have shown differences in patient survival according to geographical regions, independently of education, insurance or income, suggesting that local healthcare infrastructure might affect outcome.4 Specifically, it is observed that patients treated in an academic centre have lower early and late mortality rates while underlying reasons for these observed survival differences are not fully understood.5 6
No takes yet. Share an insight, caveat, or question.
Corentin Orvain (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: